INAB(INAB)
INAB
ANALYST COVERAGE4 analysts
BUY
▲ +139.5%upside to target
PRICE
Prev Close
1.68
Open
1.67
Day Range1.63 – 1.69
1.63
1.69
52W Range1.17 – 5.61
1.17
5.61
11% of range
VOLUME & SIZE
Avg Volume
64.3K
FUNDAMENTALS
P/E Ratio
-0.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
52
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 108 days
Sep 8
INAB News
About
in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
William Ho
Website
Kate RochlinPresident & COO
Lawrence S. LambExecutive Vice President, Co-Founder & Chief Scientific Officer
Patrick McCallChief Financial Officer & Secretary
Tai-WeiCo-Founder, CEO & Director